Patents by Inventor Seth Alexander Ettenberg

Seth Alexander Ettenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20210008201
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodies or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Application
    Filed: July 27, 2020
    Publication date: January 14, 2021
    Inventors: Winfried ELIS, Seth Alexander ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Xizhong HUANG, Christian Carsten Silvester KUNZ, Elizabeth Anne REISINGER SPRAGUE, Qing SHENG
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20190345250
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: December 19, 2018
    Publication date: November 14, 2019
    Applicant: NOVARTIS AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Matthew John Meyer, Konstanin Petropoulos, Engin Toksoz
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20190216924
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Application
    Filed: August 28, 2018
    Publication date: July 18, 2019
    Inventors: Winfried ELIS, Seth Alexander ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Xizhong HUANG, Christian Carsten Silvester KUNZ, Elizabeth Anne REISINGER SPRAGUE, Qing SHENG
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20190194347
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Application
    Filed: September 11, 2018
    Publication date: June 27, 2019
    Inventors: Winfried ELIS, Seth Alexander ETTENBERG, Andrew Paul GARNER, Nicole HAUBST, Christian Carsten Silvester KUNZ, Elizabeth Anne Reisinger SPRAGUE
  • Antibodies for epidermal growth factor receptor 3 (HER3)
    Patent number: 10077317
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Andrew Paul Garner, Elizabeth Anne Reisinger Sprague, Seth Alexander Ettenberg, Christian Kunz, Nicole Haubst, Winfried Elis
  • ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
    Publication number: 20170166653
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Application
    Filed: May 16, 2014
    Publication date: June 15, 2017
    Applicant: NOVARTIS AG
    Inventors: Andrew Paul GARNER, Elizabeth Anne Reisinger SPRAGUE, Seth Alexander ETTENBERG, Christian KUNZ, Nicole HAUBST, Winfried ELIS
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170106095
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170008964
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 7, 2016
    Publication date: January 12, 2017
    Applicant: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen HU, David Jenkins, Matthew John Meyer, Konstantin Petropoulos, Engin Toksoz
  • Antibody drug conjugates
    Patent number: 9498532
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140308201
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140301946
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Antibodies for epidermal growth factor receptor 3 (HER3)
    Patent number: 8735551
    Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Andrew Paul Garner, Elizabeth Anne Reisinger Sprague, Seth Alexander Ettenberg, Christian Kunz, Nicole Haubst, Winfried Elis
  • METHODS OF TREATING SQUAMOUS CELL CARCINOMA
    Publication number: 20140056912
    Abstract: The disclosure relates to methods for treating a sclerostin-expressing cancer, e.g., a squamous cell carcinoma (SCC), e.g., SCC of the upper aerodigestive tract, esophagus, or lung, employing a therapeutically effective amount of at least one sclerostin antagonist, e.g., an anti-sclerostin antibody, such as Antibody 1, 2, 3, 4 or 5.
    Type: Application
    Filed: April 27, 2012
    Publication date: February 27, 2014
    Applicant: Novartis AG
    Inventors: Seth Alexander Ettenberg, Vivien W. Chan, Michael Patrick Morrissey, David Jenkins